Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Inger Brandsma, Emmy D.G. Fleuren, Chris T. Williamson & Christopher J. Lord. (2017) Directing the use of DDR kinase inhibitors in cancer treatment. Expert Opinion on Investigational Drugs 26:12, pages 1341-1355.
Read now
Read now
Articles from other publishers (17)
Xingxuan Wu, Shibin Xu, Peipei Wang, Zhao-Qi Wang, Hongxiang Chen, Xingzhi Xu & Bin Peng. (2022) ASPM promotes ATR-CHK1 activation and stabilizes stalled replication forks in response to replication stress. Proceedings of the National Academy of Sciences 119:40.
Crossref
Crossref
Sabba Mehmood, Muhammad Faheem, Hammad Ismail, Syeda Mehpara Farhat, Mahwish Ali, Sidra Younis & Muhammad Nadeem Asghar. (2022) ‘Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics’. Frontiers in Molecular Biosciences 9.
Crossref
Crossref
Hannah Pook & Siim Pauklin. (2021) Mechanisms of Cancer Cell Death: Therapeutic Implications for Pancreatic Ductal Adenocarcinoma. Cancers 13:19, pages 4834.
Crossref
Crossref
Luigia Stefania Stucci, Valeria Internò, Marco Tucci, Martina Perrone, Francesco Mannavola, Raffaele Palmirotta & Camillo Porta. (2021) The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice. Genes 12:5, pages 727.
Crossref
Crossref
Weining Chen. (2021) Exploring the effects of CDK7 inhibition by YKL-5-124 on the molecular mechanisms and the ways it triggers cytokines production in Small Cell Lung Cancer in vitro. E3S Web of Conferences 245, pages 03027.
Crossref
Crossref
Marcelo Santos da Silva, Priscila Hess Lopes, Maria Carolina Elias & Denise V. Tambourgi. (2020) Cytotoxic and genotoxic effects on human keratinocytes triggered by sphingomyelinase D from Loxosceles venom. Archives of Toxicology 94:10, pages 3563-3577.
Crossref
Crossref
Masahiro Uehara, Tetsuro Kusaba, Tomoharu Ida, Kunihiro Nakai, Tomohiro Nakata, Aya Tomita, Noriko Watanabe-Uehara, Kisho Ikeda, Takashi Kitani, Noriyuki Yamashita, Yuhei Kirita, Satoaki Matoba, Benjamin D. Humphreys & Keiichi Tamagaki. (2020) Pharmacological inhibition of ataxia-telangiectasia mutated exacerbates acute kidney injury by activating p53 signaling in mice. Scientific Reports 10:1.
Crossref
Crossref
Apostolos Klinakis, Dimitris Karagiannis & Theodoros Rampias. (2019) Targeting DNA repair in cancer: current state and novel approaches. Cellular and Molecular Life Sciences 77:4, pages 677-703.
Crossref
Crossref
Lin Mei, Junran Zhang, Kai He & Jingsong Zhang. (2019) Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand. Journal of Hematology & Oncology 12:1.
Crossref
Crossref
Valentina Restelli, Monica Lupi, Rosaria Chilà, Micaela Vagni, Chiara Tarantelli, Filippo Spriano, Eugenio Gaudio, Francesco Bertoni, Giovanna Damia & Laura Carrassa. (2019) DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas. Molecular Cancer Therapeutics 18:7, pages 1255-1264.
Crossref
Crossref
Omar L. Kantidze, Artem K. Velichko, Artem V. Luzhin, Nadezhda V. Petrova & Sergey V. Razin. (2018) Synthetically Lethal Interactions of ATM, ATR, and DNA-PKcs. Trends in Cancer 4:11, pages 755-768.
Crossref
Crossref
Emilio Lecona & Oscar Fernandez-Capetillo. (2018) Targeting ATR in cancer. Nature Reviews Cancer 18:9, pages 586-595.
Crossref
Crossref
Anna Strzeszewska, Olga Alster, Grażyna Mosieniak, Agata Ciolko & Ewa Sikora. (2018) Insight into the role of PIKK family members and NF-кB in DNAdamage-induced senescence and senescence-associated secretory phenotype of colon cancer cells. Cell Death & Disease 9:2.
Crossref
Crossref
Nicola Curtin & John Pollard. 2018. Targeting the DNA Damage Response for Anti-Cancer Therapy. Targeting the DNA Damage Response for Anti-Cancer Therapy
63
97
.
Laura Carrassa & Giovanna Damia. (2017) DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy. Cancer Treatment Reviews 60, pages 139-151.
Crossref
Crossref
Rui Liu, Jiajia Tang, Chaodong Ding, Weicheng Liang, Li Zhang, Tianke Chen, Yan Xiong, Xiaowei Dai, Wenfeng Li, Yunsheng Xu, Jin Hu, Liting Lu, Wanqin Liao & Xincheng Lu. (2017) The depletion of ATM inhibits colon cancer proliferation and migration via B56γ2-mediated Chk1/p53/CD44 cascades. Cancer Letters 390, pages 48-57.
Crossref
Crossref
Michael Choi, Thomas Kipps & Razelle Kurzrock. (2016) ATM Mutations in Cancer: Therapeutic Implications. Molecular Cancer Therapeutics 15:8, pages 1781-1791.
Crossref
Crossref